Claims for Patent: 7,361,787

Summary for Patent: 7,361,787

Title:	Phenethanolamine derivatives for treatment of respiratory diseases
Abstract:	The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases ##STR00001##
Inventor(s):	Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	10/489,569
Patent Claims:	1. A compound of formula (I) ##STR00023## or a salt, solvate, or physiologically functional derivative thereof, wherein: m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m+n is 4 to 10; R.sup.1 is selected from hydrogen, C.sub.1-6alkyl, hydroxy, halo, C.sub.1-6haloalkyl, --XC(O)NR.sup.9R.sup.10, --XNR.sup.8C(O)R.sup.9, --XNR.sup.8C(O)NR.sup.9R.sup.10, --XNR.sup.8SO.sub.2R.sup.9, --XSO.sub.2NR.sup.11R.sup.12, XNR.sup.8SO.sub.2R.sup.9R.sup.10, --XNR.sup.9R.sup.10, XN.sup.+R.sup.8R.sup.9R.sup.10, --XNR.sup.8C(O)OR.sup.9, --XCO.sub.2R.sup.9, --XNR.sup.8C(O)NR.sup.8C(O)NR.sup.9R.sup.10, --XSR.sup.9, XSOR.sup.9, and --XSO.sub.2R.sup.9; or R.sup.1 is selected from --X-aryl, --X-hetaryl, and --X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --SO.sub.2NH.sub.2, --SO.sub.2NH(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkylC.sub.1-6alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, or C.sub.1-6haloalkyl; X is --(CH.sub.2).sub.p-- or C.sub.2-6 alkenylene; p is an integer from 0 to 6, R.sup.8 and R.sup.9 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)- and R.sup.8 and R.sup.9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --CO.sub.2H, --CO.sub.2(C.sub.1-4alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), aryl(C.sub.1-6alkyl)-, aryl(C.sub.2-6alkenyl)-, aryl(C.sub.2-6alkynyl)-, hetaryl(C.sub.1-6alkyl)-, --NHSO.sub.2aryl, --NH(hetarylC.sub.1-6alkyl), --NHSO.sub.2hetaryl, --NHSO.sub.2(C.sub.1-6alkyl), --NHC(O)aryl, or --NHC(O)hetaryl: R.sup.10 is selected from hydrogen, C.sub.1-6alkyl and C.sub.3-7 cycloalkyl; R.sup.11 and R.sup.12 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)-, or R.sup.11 and R.sup.12,together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; and R.sup.11 and R.sup.12 are each optionally substituted by one or two groups independently selected from halo, C.sub.1-6alkyl, and C.sub.1-6haloalkyl; where R.sup.1 is --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.8 and R.sup.9 may, together with the --NC(O)N-- portion of the group R.sup.1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring; where R.sup.1 is --XNR.sup.8C(O)OR.sup.9, R.sup.8 and R.sup.9 may, together with the --NC(O)O-- portion of the group R.sup.1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring; where R.sup.1 is --XC(O)NR.sup.9R.sup.10 or --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.9 and R.sup.10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; R.sup.2 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6 haloalkyl; R.sup.3 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6haloalkyl; R.sup.4 and R.sup.5 are independently selected from hydrogen and C.sub.1-4 alkyl with the proviso that the total number of carbon atoms in R.sup.4 and R.sup.5 is not more than 4; and, R.sup.6 and R.sup.7 are independently selected from hydrogen and C.sub.1-4alkyl with the proviso that the total number of carbon atoms in R.sup.4 and R.sup.5is not more than 4. 2. A compound of formula (I) ##STR00024## or a salt, solvate, or physiologically functional derivative thereof, wherein: m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m+n is 4 to 10; R.sup.1 is selected from hydrogen, C.sub.1-6alkyl, hydroxy, halo, C.sub.1-6haloalkyl, --XC(O)NR.sup.9R.sup.10, --XNR.sup.8C(O)R.sup.9, --XNR.sup.8C(O)NR.sup.9R.sup.10, --XNR.sup.8SO.sub.2R.sup.9, --XSO.sub.2NR.sup.11R.sup.12; --XNR.sup.9R.sup.10, --XNR.sup.8C(O)OR.sup.9, or R.sup.1 is selected from --X-aryl, --X-hetaryl, or --X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --SO.sub.2NH.sub.2, --SO.sub.2NH(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkylC.sub.1-6alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, or C.sub.1-6haloalkyl; X is --(CH.sub.2).sub.p-- or C.sub.2-6 alkenylene; p is an integer from 0 to 6, R.sup.8 and R.sup.9 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)- and R.sup.8 and R.sup.9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --CO.sub.2H, and --CO.sub.2(C.sub.1-4alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), aryl(C.sub.1-6alkyl)-, aryl(C.sub.2-6alkenyl)-, aryl(C.sub.2-6alkynyl)-, hetaryl(C.sub.1-6alkyl)-, --NHSO.sub.2aryl, --NH(hetarylC.sub.1-6alkyl), --NHSO.sub.2hetaryl, --NHSO.sub.2(C.sub.1-6alkyl), --NHC(O)aryl, or --NHC(O)hetaryl: R.sup.10 is selected from hydrogen, C.sub.1-6alkyl and C.sub.3-7 cycloalkyl; R.sup.11 and R.sup.12 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)-, or R.sup.11 and R.sup.12, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; and R.sup.11 and R.sup.12 are each optionally substituted by one or two groups independently selected from halo, C.sub.1-6alkyl, and C.sub.1-6haloalkyl; where R.sup.1 is --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.8 and R.sup.9 may, together with the portion --NC(O)N-- of the group R.sup.1 to which they are bonded, form a 5-, 6-, or 7-membered saturated or unsaturated ring; where R.sup.1 is --XNR.sup.8C(O)OR.sup.9, R.sup.8 and R.sup.9 may, together with the portion --NC(O)O-- of the group R.sup.1 to which they are bonded, form a 5-, 6-, or 7-membered saturated or unsaturated ring; where R.sup.1 is --XC(O)NR.sup.9R.sup.10 or --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.9 and R.sup.10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; R.sup.2 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6 haloalkyl; R.sup.3 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6haloalkyl; R.sup.4 and R.sup.5 are independently selected from hydrogen and C.sub.1-4 alkyl with the proviso that the total number of carbon atoms in R.sup.4 and R.sup.5 is not more than 4; and, R.sup.6 and R.sup.7 are independently selected from hydrogen and C.sub.1-4alkyl with the proviso that the total number of carbon atoms in R.sup.4 and R.sup.5 is not more than 4. 3. A compound according to claim 1 of formula (Ia) ##STR00025## or a salt, solvate, or physiologically functional derivative thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6 and R.sup.7 are as defined for claim 1 and m is 4 or 5. 4. A compound according to any one of claims 1 to 3 which is selected from: N-{3-[(2-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]- ethyl}-amino)hexyl]oxy}ethoxy)methyl]phenyl}-N'-phenylurea; 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; N-(3-{[({3-[(2-{[6-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]- ethyl}-amino)hexyl]oxy}ethoxy)methyl]phenyl}amino)carbonyl]amino}phenyl)py- ridine-3-carboxamide; 4-{(1R)-1-Hydroxy-2-[(6-{2-[(3-hydroxybenzyl)oxy]ethoxy}hexyl)amino]ethyl- }-2-(hydroxymethyl)phenol; 4-{(1R)-2-[(6-{2-[(3,5-Dimethylbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; N-{3-[(2-{[5-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}- amino)pentyl]oxy}ethoxy)methyl]phenyl}-N'-phenylurea; and salts, solvates, and physiologically functional derivatives thereof. 5. A pharmaceutical formulation comprising a compound according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients. 6. A combination comprising a compound according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and one or more other therapeutic ingredients. 7. A combination according to claim 6 wherein the other therapeutic ingredient is a PDE4 inhibitor, a corticosteroid or an anti-cholinergic agent. 8. A combination according to claim 7 wherein the additional therapeutic ingredient is 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarbonyl)oxy]-11.beta.-hy- droxy-16.alpha.-methyl-3-oxo-androsta-1,4-diene-17.beta.-carbothioic acid S-fluoromethyl ester. 9. A method for the prophylaxis or treatment of a clinical condition in a mammal, for which a selective .beta..sub.2-adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. 10. A process for preparing a compound as defined according to any one of claims 1 to 3, wherein said process is one of (A), (B) or (C): (A) deprotecting a protected intermediate of formula (II): ##STR00026## or a salt or solvate thereof, wherein R.sup.4, R.sup.5, R.sup.6, R.sup.7, m, and n are as defined for the compound of formula (I) or (Ia), and R.sup.1a, R.sup.2a, and R.sup.3a are each independently either the same as R.sup.1, R.sup.2, and R.sup.3 respectively as defined for the compound of formulae (I) or (Ia) or a precursor for said group R.sup.1, R.sup.2, or R.sup.3, and R.sup.13, R.sup.14, and R.sup.15 are each independently either hydrogen or a protecting group provided that at least one of R.sup.13, R.sup.14, and R.sup.15 is a protecting group, and R.sup.19 is hydrogen or a protecting group; (B) alkylating an amine of formula (XIX): ##STR00027## wherein R.sup.13, R.sup.14, R.sup.15 and R.sup.19 are as hereinbefore defined, with a compound of formula (VI): ##STR00028## wherein L.sup.1 represents a leaving group such as halo, and removing any protecting groups present on the alkylated compound; and (C) reacting an amine of formula (XIX) as defined hereinabove, with a compound of formula (XX): ##STR00029## wherein R.sup.4, R.sup.6, R.sup.7, R.sup.1a, R.sup.2a, R.sup.3a, m and n are as hereinbefore defined; under conditions suitable to effect reductive amination, wherein any one of (A), (B), or (C) may optionally employ one or more of the following steps in any order: (i) removing any protecting groups; (ii) separating an enantiomer or diastereoisomer from a mixture of enantiomers or diastereoisomers; (iii) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof. (iv) converting a group R.sup.1a, R.sup.2a and/or R.sup.3a to a group R.sup.1, R.sup.2 and/or R.sup.3 respectively. 11. A compound of formula (I) according to claim 1 wherein the group R.sup.1 is attached to the meta-position relative to the --OCR.sup.6R.sup.7--link. 12. A compound of formula (I) according to claim 1, wherein the groups R.sup.2 and R.sup.3 are each independently attached to the ortho position relative to the --OCR.sup.6R.sup.7--link. 13. A compound of formula (I) according to claim 3 wherein R.sup.1 represents a substituent other than hydrogen, attached to the meta-position relative to the --OCR.sup.6R.sup.7--link, and R.sup.2 and R.sup.3 each represent hydrogen. 14. A compound of formula (I) according to claim 1 wherein R.sup.1 represents hydrogen and R.sup.2 and R.sup.2 each represent a substituent at least one of which is other than hydrogen, and R.sup.2 and R.sup.3 are each independently attached to the ortho- or meta-positions relative to the --OCR.sup.6R.sup.7--link. 15. A compound of formula (I) according to claim 1 wherein R.sup.1 is selected from the group consisting of hydrogen, C.sub.1--6alkyl, hydroxy, halo, C.sub.1--6haloalkyl, --XNR.sup.8(C)OR.sup.9, --XNR.sup.8C(O)NR.sup.9R.sup.10, --XNR.sup.8SO.sub.2R.sup.9, --XSO.sub.2NR.sup.11R.sup.12, --XNR.sup.9R.sup.10, --XNR.sup.8C(O)OR.sup.9, XSR.sup.9, XSOR.sup.9, XSO.sub.2R.sup.9, X-aryl, X-hetaryl and X-aryloxy. 16. A compound of formula (I) according to claim 1 wherein X is (CH.sub.2).sub.p and p is zero. 17. A compound of formula (I) according to claim 1 wherein R.sup.1 is selected from the group consisting of hydrogen, C.sub.1--4alkyl, hydroxy, halo, --NR.sup.8C(O)NR.sup.9R.sup.10, and --NR.sup.8SO.sub.2R.sup.9. 18. A compound of formula (I) according to claim 1, wherein R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, halogen, haloC.sub.1--6alkyl, C.sub.1--6alkyl, phenyl, and substituted phenyl. 19. A compound of formula (I) according to claim 1, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen, and methyl. 20. A compound of formula (I) according to claim 1, wherein R.sup.6 and R.sup.7 are independently selected from the group consisting of hydrogen, and methyl. 21. A compound of formula (I) according to claim 1, wherein m is 4, 5, or 6, and n is 2 or 3. 22. An inhalation device comprising the compound according to claim 1. 23. An inhalation device according to claim 22, wherein the compound is present in particles ranging in size from 1 .mu.m to 10 .mu.m. 24. An inhalation device according to claim 22, wherein the compound is present in a dry powder pharmaceutical formulation. 25. An inhalation device according to claim 22, wherein the compound is present in an aerosol pharmaceutical formulation.